Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Trial of Tenecteplase vs. Alteplase in Acute Ischemic Stroke

Next Previous
Trial Profile

A Randomised Trial of Tenecteplase vs. Alteplase in Acute Ischemic Stroke

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenecteplase (Primary) ; Alteplase
  • Indications Ischaemic stroke
  • Focus Therapeutic Use
  • Acronyms NOR-TEST 2

Most Recent Events

  • 14 Sep 2023 Status changed from recruiting to discontinued.
  • 30 May 2022 Primary endpoint has not been met. (Proportion of patients with favorable functional outcome for part A tenecteplase 0.4 mg/kg), as per Results published in the Lancet Neurology
  • 30 May 2022 Results(n=216) published in the Lancet Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top